[citado 12 oct 2010] disponible en:
http://www.sap.org.ar/staticfiles/actividades/congresos/congre2007/alergia/mesas/4.pdf
5. Capristo C;Rigotti E;Boner A.Update on the use of Montelukast in pediatric asthma. Allergy Asthma Proc. 2006;27:312- 318.
6. Bergone C, MD, MSc;Boulet L, MD, FCCP. Structural Changes in Airway Diseases. Chest. 2009;129:1068 –87.
7. Bentley AM, Jacobson MR, Cumberworth V, Barkans JR, Moqbel R, Schwartz LB, et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis:increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol. 2008;89:877–883.
8. Juliusson S, Pipkorn U, Karlsson G, Enerback L. Mast cells and eosinophils in the allergic mucosal response to allergen challenge:changes in distribution and signs of activation in relation to symptoms. J Allergy Clin Immunol. 2008;90:898–909.
9. Hakansson L, Rak S, Dahl R, Venge P. The formation of eosinophil and neutrophil chemotactic activity during a pollen season and after allergen challenge. J Allergy Clin Immunol. 2009;83:933–939.
10. Fokkens WJ, Broekhuis-Fluitsma DM, Rijntjes E, Vroom TM, Hoefsmit EC. Langerhans cells in nasal mucosa of patients with grass pollen allergy. Immunobiology. 2001;182:135–42.
11. Naclerio RM, Meier HL, Kagey-Sobotka A, Adkinson NF, Meyers DA, Norman PS, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis. 2009;128:597–602.
12. Wang D, Clement P, Smitz J, De Waele M, Derde M-P. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergenchallenge and during natural allergen exposure. Int Arch Allergy Immunol. 2009;106:278–85.
13. Knani J, Campbell A, Enander I, Peterson CGB, Michel F-B, Bousquet J. Indirect evidenceof nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol. 2008;90:880–9.
14. Wilson SJ, Lau L, Howarth PH. Inflammatory mediators in naturally occurring rhinitis. Clin Exp Allergy. 2008;28:220–227.
15. Mygind N, Secher C, Kirkegaard J. Role of histamine and antihistamines in the nose. Eur J Respir Dis. 2009;64:16–20.
16. Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy. 2007;52:12–8.
17. Rinitis alérgica y asma. ¿dos caras de la misma moneda?.[monografía en Internet]. Madrid:GINA. 2009;[citado 12 oct 2010] Disponible en:
http://www.consejos-e.com/Terminos/asma%20rinitis_4737.html
18. Berbés A. Montelukast reduce a la vez los síntomas de la rinitis alérgica y del asma. [monografia en Internet][. Madrid: Accesogroup S.L. 2009[citado 10 oct 2010] Disponible en:
http://www.acc.berbes.es/leucotrienos/diplay_release.html?id=71018
19. Capristo C;Rigotti E;Boner A.Update on the use of Montelukast in pediatric asthma. Allergy Asthma Proc. 2006;27:312-8.
20. Bergone C, MD, MSc;Boulet L, MD, FCCP. Structural Changes in Airway Diseases. Chest. 2009;129:1068– 87.
21. Handerson W R;Chiang G K;Tien Y T;Chi EY. Reversal of allergen–induced airway remodeling by CysLT 1 receptor blockade. Am J Respir Crit Care Med. 2006;173:718-28.
22. E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald. Global strategy for asthma management and prevention:GINA executive summary.Cockcroft Eur Respir J. 2008;31:143-78.
23. Dunn CJ, Goa KL. Zafirlukast an update of its pharmacology and therapeutic efficacy in asthma. Drugs. 2001;61(2) 285-315.
24. McGill KA, Busse WW. Zileuton. Lancet. 1996;348:519-524.
25. Pérez de Llano LA, Veres A, Parra A. Síndrome de Strauss en un paciente asmático tratado con Montelukast: continuación de una controversia. Arch Bronconeumol. 2008;38(5):251.
26. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2009;128:1910-20
27. Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB, Reiss TF. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin. 2004;20(10):1549-58.
28. Asma y rinitis, tratamiento conjunto. [Monografía en Internet]. Madrid: Difusiones Tecnológicas de Mercado, S.L., [citado 12 dic 2010] Disponible en:
http://www.consejos-e.com/Terminos/asma%20rinitis_4737.html
29. Mortana A. Montelukast acción sobre los síntomas de la rinitis alérgica y del asma. [Monografía en Internet]. Madrid: Academia Europea de Alergología e Inmunología Clínica (EAACI), [citado 12 dic 2010] Disponible en:
http://berbes.com.es/academiaEuropeadeAlergologíaInmunologíaClínica(EAACI)/5685/montelukast/pdf/hytr5·$/pdf
30. Dahlén, S-E. Cysteinyl leukotrienes as common mediators of asthma and allergic disease. Clínical Experimental Allergy Reviews. [Internet]. 2009 [citado 23 oct 2010];3(2)[aprox. 5 p.]. Disponible en:
http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=9584854&lang=es&site=ehost-live
31. Zeidler MR, Kleerup EC, Goldin JG y colaboradores. Montelukast Improves Regional Air-Trapping due to Small Airways Obstruction in Asthma. European Resp J. 2006:27(2):307-315.
32. Van Adelsberg J, Philip G, Laforce CF, Weinstein SF, Menten J, Malice MP, et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2009;90:2:214-22.
33. Philip G, MAlmstrom K, Hampel FC JR, Wenstein SF, Laforce CF, Ratner PH, et al. Montelukast treating seasonal allergic rhinitis:a randomized, double-blind, placebo-controlled trial preformed in the spring. Ciln Exp Allergy. 2008;32:7:1020-8.
34. Philip G, Weinstein SF, Malmstron K, Marchal JL, Reiss TF. Montelukast improves daily composite symptoms score in patients with seasonal allergic rhinitis in double-blind, randomised, placebo-controlled studies. Am J Respir Crit Care Med. 2008;165:8:A327.